DEALS: Pfizer, BMS ink billion dollar deal


Pfizer, BMS ink billion dollar deal


DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Bristol-Myers Squibb

$1B deal

Pfizer has agreed to pay $250 million up front and up to $750 million in milestones to partner with BMS on apixaban, a blood clot therapy that has demonstrated promising efficacy and could go on to become a successor for Coumadin.

Peptech

EvoGenics

$156M acquisition

Australia's Peptech is acquiring rival antibody therapeutics player EvoGenics in a cash/shares deal worth $156 million.

BMS

Isis Pharmaceuticals

Development deal

The companies collaborate on the discovery, development and commercialization of antisense drugs targeting the gene PCSK9 for cardiovascular disease.

Genentech

Sangamo BioSciences

Research and licensing agreement

Sangamo BioSciences will provide Genentech with its zinc finger DNA-binding protein technology along with ZFP nucleases to generate cell lines with characteristics for protein pharmaceutical production purposes.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.